CD274 and neoplasm: Inhibition of glycosylation has potential in tumor immunosuppression.258 Li et al. found that targeting glycosylated PD-L1 and blocking PD-L1/PD-1 interactions promoted PD-L1 internalization and degradation, and was able to eradicate TNBC cells.181 Monoclonal antibodies targeting glycosylation have become another direction of immune checkpoint therapy.